Tradestie Institutional Equity Comparison Engine

ABUS vs SNYR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABUS Overall Edge

ABUS Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SNYR counters with relative strength in Valuation. Fundamentally, ABUS trades at 10.2x Forward P/E with 80.1% operating margin (-43.5% YoY revenue) versus SNYR at 0.6x Forward P/E and -10.3% operating margin (-32.8% YoY). In options structure, ABUS sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against SNYR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner SNYR
ABUS 10.2x vs SNYR 0.6x Fwd P/E
Growth & Margin Winner ABUS
Op Margin 80.1% vs -10.3% ยท YoY -43.5% vs -32.8%
Momentum & Technical Winner ABUS
1Y -5.8% vs -96.2% ยท 52W Pos 27% vs 1%
Options & Structure Winner ABUS
CONSOLIDATION (18th %ile IV) vs UNCLASSIFIED (N/A IV)
ABUS NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.02
-1.23% 1D
Market Cap $623.9M
1M Return -4.51%
1Y Return -5.85%
Forward P/E 10.2x
Unified AI Score
43.4 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 68.0 Mom 53.7
SNYR NASDAQ
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
1M Return -16.28%
1Y Return -96.15%
Forward P/E 0.6x
Unified AI Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABUS -5.85% SNYR -96.15% Spread: +114.87 pp (ABUS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ABUS Revenue SNYR Revenue ABUS Op. Margin SNYR Op. Margin Margin Edge
FY2018 $10M $30M -1510.2% -14.5% SNYR
FY2019 $10M $30M -2394.0% -27.1% SNYR
FY2020 $10M N/A -836.1% N/A ABUS
FY2021 $10M N/A -669.1% N/A ABUS
FY2022 $40M N/A -167.8% N/A ABUS
FY2023 $20M $40M -430.5% 25.3% SNYR
FY2024 $10M $30M -1236.7% 16.7% SNYR
FY2025 $10M $30M -271.0% -27.8% SNYR

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABUS (6) vs SNYR (4)
Institutional Metric ABUS SNYR Criterion Row Winner
Market Capitalization Scale $623.9M $4.1M Larger Scale ABUS
Trailing P/E Ratio Valuation 3.6x 0.6x Lower Multiple SNYR
Forward P/E Ratio Valuation 10.2x 0.6x Lower Multiple SNYR
Revenue Growth (YoY) Growth -43.5% -32.8% Higher Growth SNYR
Operating Margin (TTM) Profitability 80.1% -10.3% Higher Margin ABUS
Net Profit Margin Profitability 121.2% -57.0% Higher Margin ABUS
Return on Equity (ROE) Capital Efficiency 269.6% -361.1% Higher ROE ABUS
52-Week Range Position Momentum 27% ($4โ€“$5) 1% ($0โ€“$3) Stronger Trend ABUS
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 48% Vol -0.86ฮฒ ยท 868% Vol Lower Realized Risk ABUS
Unified Institutional Score Composite Signal 43.4 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite SNYR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABUS vs SNYR Buy Guide
ABUS CONSOLIDATION
96d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 18th %ile
IV Regime Compressed (<25th %ile)
Live ABUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SNYR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SNYR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABUS nor SNYR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.